Vicarious Surgical

Vicarious Surgical, Inc. engages in advancing the field of surgical robotics. Through the use of surgical robotics, the company aims to improve patients lives, surgeons abilities, and expand global access to high-quality care. The company was founded by Adam Sachs and Sammy Khalifa on May 6, 2020 and is headquartered in Waltham, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vicarious Surgical reports progress in procedures and system development

Vicarious Surgical demonstrated strong performance in Q4 2022 with successful procedures and system advancements.
While facing financial challenges, the company's strategic strengths and opportunities position them for future growth.
Maintaining a balance between innovation, cost management, and regulatory milestones will be key for Vicarious Surgical.

Vicarious Surgical reports Q1 progress amidst regulatory discussions and innovation

Vicarious Surgical's Q1 2023 performance reflects progress in refining their robotic system and managing expenses, with a strong cash position and ongoing FDA discussions.
The company's strengths lie in innovation, regulatory focus, and strategic spending, positioning them well for future growth and expansion into new indications.
Challenges include high operating expenses and regulatory uncertainties, while opportunities exist in enhancing their technology and capitalizing on market potential through disciplined investments.

Vicarious Surgical reports Q2 loss, eyes FDA milestones for growth

Vicarious Surgical's Q2 performance reflects a focus on innovation, regulatory compliance, and strategic leadership.
The company's strong cash position, upcoming milestones, and product development efforts signal growth potential.
Challenges in managing expenses, regulatory hurdles, and market competition require careful navigation and strategic planning.
Opportunities lie in expanding partnerships, FDA approvals, and leveraging the demand for minimally invasive surgical solutions.

Vicarious Surgical reports improved finances but faces delays in flagship program

Vicarious Surgical navigated challenges with financial improvements but faces delays in their flagship program. Despite setbacks, the company remains committed to revolutionizing robotic surgery and enhancing capital efficiency.

Vicarious Surgical reports progress in product development and funding

Vicarious Surgical navigated challenges in 2023, strengthened its product offering, and secured funding for future growth. The company's financial position is stable, with a focus on achieving milestones in 2024. Leveraging partnerships and regulatory clarity present growth opportunities.

Vicarious Surgical reports strong Q1 performance and eyes global expansion

Vicarious Surgical's Q1 2024 performance reflects financial improvements and technological advancements, positioning the company for future growth.
While facing challenges in system integration and regulatory processes, the company's strengths in technology innovation and leadership provide a strong foundation for success.
Opportunities in international expansion, strategic partnerships, and regulatory advancements present avenues for Vicarious Surgical to capitalize on its unique market position and drive long-term value.

Vicarious Surgical reports Q2 progress amidst financial challenges

Vicarious Surgical's Q2 2024 performance showed progress in system integration and partnerships, but also highlighted financial challenges.
The company's strong cash position and focus on upcoming milestones position it well for future growth opportunities.
Analyst questions underscore the need for Vicarious Surgical to address financial concerns and execute on its strategic initiatives effectively.

Vicarious Surgical reports improved financials and progresses on robotic platform

Vicarious Surgical's Q3 2024 performance showed financial improvements and progress in developing its single-port platform for robotic surgery. While challenges and uncertainties exist, the company's focus on cost management and regulatory readiness bode well for future growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vicarious Surgical, Inc. a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It also designs surgical robotics. The company was founded by Adam Sachs, Sammy Khalifa, and Barry Greene on May 1, 2014 and is headquartered in Waltham, MA.

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced the company will participate in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. A recording of the presentation will be available beginning on Monday, November 22, 2021 at 10:00 a.

Vicarious Surgical to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Vicarious Surgical Inc. (RBOT) CEO Adam Sachs on Q3 2021 Results - Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced third quarter 2021 financial results. “This quarter marks our entry into the public markets, and I am incredibly proud of our teams and employees for their contributions to our company's growth to-date. We are well positi

Vicarious Surgical Reports Third Quarter 2021 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. Management is scheduled to present on Thursday, November 18th at 4:00 p.m. Eastern Time and will part

Vicarious Surgical to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced that management will participate in the Credit Suisse 30th Annual Healthcare Conference. Management is scheduled to present on Thursday, November 11th at 3:30 p.m. Eastern Time and will participate in virtual investor mee

Vicarious Surgical to Present at the Credit Suisse 30th Annual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced it will report financial results for the third quarter 2021 after the market closes on Monday, November 8, 2021. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors

Vicarious Surgical to Report Third Quarter 2021 Financial Results on November 8, 2021

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced execution on a long term lease agreement providing an additional 30,000 square feet in Waltham, MA. The new facility will expand manufacturing facilities and include four operating rooms for demonstration and testing. The

Vicarious Surgical Enters Long-Term Lease, Expanding Footprint for Continued Growth

News for Vicarious Surgical Stock (RBOT)